A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.
Saved in:
| Title: | A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial. |
|---|---|
| Authors: | Cook JA; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Patten PEM; Comprehensive Cancer Centre, Faculty of Life Sciences and Medicine, King's College London, London, UK., Peckham N; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Moss P; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Phillips N; Department of Haematology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK., Abhishek A; Academic Rheumatology, University of Nottingham, Nottingham, UK., Roberts T; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Hodges M; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Talbot G; Department of Haematology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK., Barber V; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Francis A; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Shields AM; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Duley L; CLL Support Association, London, UK., Hoogeboom R; Faculty of Life Sciences and Medicine, King's College London, London, UK., Willett BJ; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK., Scott S; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK., Parry-Jones N; Department of Haematology, Aneurin Bevan University Health Board, Abergavenny, UK., Eyre TA; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, UK., Plested G; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Vandici G; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK., Wandroo FA; Department of Haematology, Sandwell and West Birmingham Hospitals, NHS Trust, West Bromwich, UK., Hutchinson C; Department of Haematology, University Hospitals Plymouth NHS Trust, Plymouth, UK., Paneesha S; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Murray DJ; University Hospitals Coventry and Warwickshire, Coventry, UK., Martinez-Calle N; Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Jenkins S; Department of Haematology, The Dudley Group NHS Foundation Trust, Dudley, UK., Heartin E; Department of Haematology, Betsi Cadwaladr University Health Board, Bangor, UK., Parry HM; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. Electronic address: h.m.parry@bham.ac.uk. |
| Source: | The Lancet. Haematology [Lancet Haematol] 2025 Apr; Vol. 12 (4), pp. e294-e303. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Multicenter Study; Equivalence Trial |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40175001 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Cook+JA%22">Cook JA</searchLink>; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Patten+PEM%22">Patten PEM</searchLink>; Comprehensive Cancer Centre, Faculty of Life Sciences and Medicine, King's College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Peckham+N%22">Peckham N</searchLink>; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Moss+P%22">Moss P</searchLink>; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22Phillips+N%22">Phillips N</searchLink>; Department of Haematology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.<br /><searchLink fieldCode="AU" term="%22Abhishek+A%22">Abhishek A</searchLink>; Academic Rheumatology, University of Nottingham, Nottingham, UK.<br /><searchLink fieldCode="AU" term="%22Roberts+T%22">Roberts T</searchLink>; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22Hodges+M%22">Hodges M</searchLink>; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22Talbot+G%22">Talbot G</searchLink>; Department of Haematology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.<br /><searchLink fieldCode="AU" term="%22Barber+V%22">Barber V</searchLink>; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Francis+A%22">Francis A</searchLink>; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Shields+AM%22">Shields AM</searchLink>; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22Duley+L%22">Duley L</searchLink>; CLL Support Association, London, UK.<br /><searchLink fieldCode="AU" term="%22Hoogeboom+R%22">Hoogeboom R</searchLink>; Faculty of Life Sciences and Medicine, King's College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Willett+BJ%22">Willett BJ</searchLink>; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Scott+S%22">Scott S</searchLink>; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Parry-Jones+N%22">Parry-Jones N</searchLink>; Department of Haematology, Aneurin Bevan University Health Board, Abergavenny, UK.<br /><searchLink fieldCode="AU" term="%22Eyre+TA%22">Eyre TA</searchLink>; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Plested+G%22">Plested G</searchLink>; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Vandici+G%22">Vandici G</searchLink>; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Wandroo+FA%22">Wandroo FA</searchLink>; Department of Haematology, Sandwell and West Birmingham Hospitals, NHS Trust, West Bromwich, UK.<br /><searchLink fieldCode="AU" term="%22Hutchinson+C%22">Hutchinson C</searchLink>; Department of Haematology, University Hospitals Plymouth NHS Trust, Plymouth, UK.<br /><searchLink fieldCode="AU" term="%22Paneesha+S%22">Paneesha S</searchLink>; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22Murray+DJ%22">Murray DJ</searchLink>; University Hospitals Coventry and Warwickshire, Coventry, UK.<br /><searchLink fieldCode="AU" term="%22Martinez-Calle+N%22">Martinez-Calle N</searchLink>; Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.<br /><searchLink fieldCode="AU" term="%22Jenkins+S%22">Jenkins S</searchLink>; Department of Haematology, The Dudley Group NHS Foundation Trust, Dudley, UK.<br /><searchLink fieldCode="AU" term="%22Heartin+E%22">Heartin E</searchLink>; Department of Haematology, Betsi Cadwaladr University Health Board, Bangor, UK.<br /><searchLink fieldCode="AU" term="%22Parry+HM%22">Parry HM</searchLink>; Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. Electronic address: h.m.parry@bham.ac.uk. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101643584%22">The Lancet. Haematology</searchLink> [Lancet Haematol] 2025 Apr; Vol. 12 (4), pp. e294-e303. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Multicenter Study; Equivalence Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101643584 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3026 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523026%22">23523026 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Haematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40175001 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S2352-3026(25)00008-0 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e294 Titles: – TitleFull: A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Cook JA – PersonEntity: Name: NameFull: Patten PEM – PersonEntity: Name: NameFull: Peckham N – PersonEntity: Name: NameFull: Moss P – PersonEntity: Name: NameFull: Phillips N – PersonEntity: Name: NameFull: Abhishek A – PersonEntity: Name: NameFull: Roberts T – PersonEntity: Name: NameFull: Hodges M – PersonEntity: Name: NameFull: Talbot G – PersonEntity: Name: NameFull: Barber V – PersonEntity: Name: NameFull: Francis A – PersonEntity: Name: NameFull: Shields AM – PersonEntity: Name: NameFull: Duley L – PersonEntity: Name: NameFull: Hoogeboom R – PersonEntity: Name: NameFull: Willett BJ – PersonEntity: Name: NameFull: Scott S – PersonEntity: Name: NameFull: Parry-Jones N – PersonEntity: Name: NameFull: Eyre TA – PersonEntity: Name: NameFull: Plested G – PersonEntity: Name: NameFull: Vandici G – PersonEntity: Name: NameFull: Wandroo FA – PersonEntity: Name: NameFull: Hutchinson C – PersonEntity: Name: NameFull: Paneesha S – PersonEntity: Name: NameFull: Murray DJ – PersonEntity: Name: NameFull: Martinez-Calle N – PersonEntity: Name: NameFull: Jenkins S – PersonEntity: Name: NameFull: Heartin E – PersonEntity: Name: NameFull: Parry HM IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2025 Apr Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2352-3026 Numbering: – Type: volume Value: 12 – Type: issue Value: 4 Titles: – TitleFull: The Lancet. Haematology Type: main |
| ResultId | 1 |
